Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Development of novel gene-editing systems
Company stage: Pre-clinical
Diseases (gene editing): Undisclosed
Genome editing tool: CRISPR-MAD7
Funding stage: Private
Location: Boulder, Colorado, United States
Inscripta is a company that aims to provide digital solutions for genome engineering using its Onyx™ platform. The CRISPR-based platform consists of an instrument, consumables, software, and assays and offers a fully automated workflow that enables massively parallel, trackable editing of single cells. The company also develops its proprietary MAD7 enzyme, which is a novel CRISPR nuclease. The company aims to enter into non-exclusive license agreements with other companies for the enzyme.